^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGFR3-BAIAP2L1 fusion

    i
    Other names: BAIAP2L1, BAI1 associated protein 2 like 1, Insulin receptor tyrosine kinase substrate, IRTKS, FGFR3, ACH, CD333, CEK2, JTK4, Fibroblast growth factor receptor 3
    Entrez ID:
    2261; 55971
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    almost2years
    Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. (PubMed, BMC Cancer)
    We demonstrate that increased expression of pERBB3 is a key mechanism of adaptive resistance to FGFR inhibitors in FGFR3-fusion driven bladder cancers, and that this also occurs rapidly following FGFR inhibitor treatment. Our findings demonstrate that resistance can be overcome by combination treatment with a pan-ERBB inhibitor and suggest that upfront combination treatment with FGFR and pan-ERBB inhibitors warrants further investigation for FGFR3-fusion harbouring bladder cancers.
    Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • BAIAP2L1 (BAI1 associated protein 2 like 1)
    |
    FGFR3-TACC3 fusion • FGFR3 fusion • FGFR3-BAIAP2L1 fusion
    |
    Mekinist (trametinib) • Balversa (erdafitinib) • Truseltiq (infigratinib) • Lytgobi (futibatinib) • sapitinib (AZD8931)
    almost2years
    Clinicopathological characterization, FGFR alteration prevalence, and outcomes of locally advanced or metastatic urothelial cancer in Latin America (LACOG 1518). (ASCO 2022)
    Gemcitabine-platinum combinations were the backbone of choice in 93.7% of pts receiving combined chemotherapy. Pembrolizumab and atezolizumab were the chosen first-line agents for 10.3% and 4% of the treated pts, respectively... The prevalence of FGFR alterations in advanced UC in Latin America is similar to those described in other regions. Our data suggest limited access to FGFR inhibitors for the treatment of advanced UC in Latin America.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • TACC3 (Transforming acidic coiled-coil containing protein 3) • BICC1 (BicC Family RNA Binding Protein 1) • BAIAP2L1 (BAI1 associated protein 2 like 1) • CASP7 (Caspase 7)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3-BAIAP2L1 fusion
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • gemcitabine
    over2years
    Prognostic impact of fibroblast growth factor receptor (FGFR) genomic alterations and outcomes in patients with metastatic urothelial. (ASCO-GU 2022)
    Despite a better response to first line treatment, overall FGFR GA showed to be an independent risk factor in mUC. Thus, this determination should be included in new prognostic models. Univariable and multivariable analysis for overall survival in the first line treatment setting for mUC.
    Clinical
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • BICC1 (BicC Family RNA Binding Protein 1) • BAIAP2L1 (BAI1 associated protein 2 like 1) • CASP7 (Caspase 7)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3-BAIAP2L1 fusion • FGFR wild-type
    |
    FoundationOne® CDx • therascreen® FGFR RGQ RT-PCR Kit